Frontlight ResearchEarly access
Taking people in United StatesEarly phase 1
Cocaine and Pentoxifylline (BED IN 47)
Key facts
- Who runs it
- William Stoops
- Where
- Lexington, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 30 people, planned
- Started
- 10 Nov 2025
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Placebo
- Cocaine (IV)
- Pentoxifylline
- Record updated
- 8 June 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- able to speak/read English,
- not seeking treatment for drug use at the time of the study,
- female or male between the ages of 18 and 55 years,
- recent smoked or intravenous cocaine use verified by benzoylecgonine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for CUD,
- judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for CUD at the time of screening,
- ECG, read by a cardiologist, within normal limits,
- females using an effective form of birth control and not pregnant or breastfeeding and 8) no known contraindications or allergies to pentoxifylline
Who cannot take part
- seeking treatment for drug use,
- Self-reported history of head trauma, seizure, CNS tumors, or use of concomitant medications that lower seizure threshold, or first-degree family history of seizures
- contraindications or allergies to pentoxifylline, and
- unable to speak/read English,
- under 18 years or over 55 years,
- no recent smoked or intravenous cocaine use as indicated by benzoylecgonine negative urine and no DSM-5 diagnosis of CUD,
- judged to be medically or psychiatrically unhealthy by study physicians at the time of screening,
- ECG, read by a cardiologist, outside normal limits,
- females not using an effective form of birth control or pregnant or breastfeeding,
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Where in United States
- Psychopharmacology of Addiction LaboratoryLexington, United StatesContact: William W Stoops, PhDTaking people
About the trial
What the trial wants to find out
This will be a human laboratory study evaluating the influence of pentoxifylline treatment on the effects of cocaine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.
The 3 groups in the trial
- PlaceboPlacebo, for comparison
Subjects will be treated daily with an oral placebo.
- Pentoxifylline Dose 1Treatment being tested
Subjects will be treated daily with oral pentoxifylline (1200 mg).
Treatment: Placebo, Cocaine (IV), and Pentoxifylline
- Pentoxifylline Dose 2Treatment being tested
Subjects will be treated daily with oral pentoxifylline (1600 mg).
Treatment: Placebo, Cocaine (IV), and Pentoxifylline
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study With Pentoxifylline
- Fit questions
- Built from NCT07086794, who can take part
- Record updated
- 8 June 2026